Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis

Table 4 Most common (≥ 5%) grade 3 or 4 treatment-emergent adverse events (TEAEs) reported in more than one study

Adverse events	Study ID	Intervention	Events (n)	Total (n)	Rate (%)
Lymphocytopenia	Kimmich 2021	DRd	11	44	25.0
	Kimmich 2020	Dara ± dex, DVd	27	142	20.2
	Sanchorawala 2020	Dara ± dex	3	22	13.6
Heart failure^*	Kimmich 2020	Dara ± dex, DVd	15	168	8.9
	Kaufman 2017	Dara ± dex	1	25	4.0
	Sanchorawala 2020	Dara ± dex	3	22	13.6
Infection complications	Cohen 2020	Dara ± dex	0	53	0.0
	Dima 2020	Mixed ^†	3	40	7.5
	Gounot 2020	Mixed ^†	2	25	8.0
	Kaufman 2017	Dara ± dex	2	25	8.0
	Kimmich 2020	Dara ± dex, DVd	28	168	16.0
	Milani 2020	Mixed ^†	3	72	4.2
	Sanchorawala 2020	Dara ± dex	4	22	18.2
	Shragai 2020	Mixed ^†	7	48	14.6
Pneumonia	Dima 2020	Mixed ^†	2	40	5.0
	Kimmich 2021	DRd	7	44	15.9
	Milani 2020	Mixed ^†	4	72	5.6
	Shragai 2020	Mixed ^†	5	48	10.4
Fatigue	Cohen 2020	Dara ± dex	0	53	0.0
Fatigue	Sanchorawala 2020	Dara ± dex	2	22	9.1
Atrial fibrillation	Kimmich 2020	Dara ± dex, DVd	0	168	0.0
	Milani 2020	Mixed^†	2	72	2.8
	Sanchorawala 2020	Dara ± dex	4	22	18.2
Neutropenia	Abeykoon 2018	Dara ± dex	3	44	6.8
	Kimmich 2020	Dara ± dex, DVd	0	142	0.0
	Milani 2020	Mixed^†	2	72	2.8
Diarrhea	Cohen 2020	Dara ± dex	0	53	0.0
	Kimmich 2020	Dara ± dex	1	168	0.6
	Sanchorawala 2020	Dara ± dex	2	22	9.1
	Shragai 2020	Mixed^†	1	48	2.1

Dara ± dex Daratumumab ± Dexamethasone, DVd Daratumumab + Bortezomib + Dexamethasone
^*Including congestive heart failure and decompensated heart failure
^†Mixed Daratumumab-based treatments indicate there were more than one kind of daratumumab-based treatment in the study (daratumumab was combined with dexamethasone, bortezomib, lenalidomide, pomalidomide, cyclophosphamide, ixazomid, or carfilzomib)

ISSN: 1475-2867